Register Now for NAAF's 39th Annual Patient Conference June 27-30, 2024 in Washington, D.C.!

A Study to Evaluate the Safety of an Investigational Topical JAK Inhibitor Suspension in Adults with Alopecia Areata

Study type: Clinical Trials Posting date: 05/22/2023 Last updated: 05/22/2023 Status: Recruiting Phase: Phase 1 Country: United States Eligibility:

18 to 70 years of age; have patchy alopecia areata

Drug: Investigational JAK Inhibitor Administration: Topical Sponsor: Arcutis Biotherapeutics Sponsor Link: Click here Location: Multiple locations


This study is being done for research purposes to evaluate the safety and tolerability of applying a topical form of an investigational JAK inhibitor in adults with alopecia areata.

You may qualify to participate in this study if you:*

  • Are 18 to 70 years of age
  • Have patchy alopecia areata

*There are additional requirements as determined by a screening process.–

If you qualify, you will need to come to the study center up to 7 times over a 4 month period. At these visits, the study doctor will closely monitor your alopecia areata and discuss your overall experiences with the study drug and your participation in the study.

This study is taking place at locations throughout the United States.

Please visit for more information.